Triple negative breast cancer (TNBC), which lacks expression of the estrogen receptor, progesterone receptor and HER2/neu (HER2), accounts for 10% to 20% of breast cancer cases [2, 3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.